News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Mar 5, 2021 9:39 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Feb 17, 2021
Forma Therapeutics to Participate in Upcoming Investor Conferences
Jan 20, 2021
Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jan 11, 2021
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Upcoming Events
Mar 17, 2021
8:40 AM EDT
Oppenheimer 31st Annual Healthcare Conference
Learn more
Mar 9, 2021
7:00 AM EST
H.C. Wainwright Global Life Sciences Conference
Learn more
Feb 24, 2021
1:40 PM EST
SVB Leerink 10th Annual Global Healthcare Conference
Learn more